Diabetes & Metabolism Journal

Gwanpyo Koh (Koh G)

6 Articles

Enhancing Patient Outcomes: Prioritizing SGLT2is and GLP-1RAs in Diabetes with CVD: Gwanpyo Koh; Diabetes Metab J. 2024;48(2):208-212. Published online March 22, 2024; DOI: https://doi.org/10.4093/dmj.2024.0096

2,228 View
222 Download
1 Web of Science
1 Crossref

PDF PubReader ePub

Citations

Citations to this article as recorded by

Bibliometric and visual analysis of SGLT2 inhibitors in cardiovascular diseases
Runfang Pan, Yuqing He, Wan Melisandre, Yunyi Zhang, Wenyuan Su, Jiaming Feng, Chengyao Jia, Shaoling Li, Baonian Liu
Frontiers in Pharmacology.2024;[Epub] CrossRef

Metabolic Risk/Epidemiology
Current Status of Low-Density Lipoprotein Cholesterol Target Achievement in Patients with Type 2 Diabetes Mellitus in Korea Compared with Recent Guidelines: Soo Jin Yun, In-Kyung Jeong, Jin-Hye Cha, Juneyoung Lee, Ho Chan Cho, Sung Hee Choi, SungWan Chun, Hyun Jeong Jeon, Ho-Cheol Kang, Sang Soo Kim, Seung-Hyun Ko, Gwanpyo Koh, Su Kyoung Kwon, Jae Hyuk Lee, Min Kyong Moon, Junghyun Noh, Cheol-Young Park, Sungrae Kim; Diabetes Metab J. 2022;46(3):464-475. Published online March 3, 2022; DOI: https://doi.org/10.4093/dmj.2021.0088

9,323 View
411 Download
8 Web of Science
11 Crossref

Abstract PDF Supplementary Material PubReader ePub

Background
We evaluated the achievement of low-density lipoprotein cholesterol (LDL-C) targets in patients with type 2 diabetes mellitus (T2DM) according to up-to-date Korean Diabetes Association (KDA), European Society of Cardiology (ESC)/European Atherosclerosis Society (EAS), and American Diabetes Association (ADA) guidelines.
Methods
This retrospective cohort study collected electronic medical record data from patients with T2DM (≥20 years) managed by endocrinologists from 15 hospitals in Korea (January to December 2019). Patients were categorized according to guidelines to assess LDL-C target achievement. KDA (2019): Very High-I (atherosclerotic cardiovascular disease [ASCVD]) <70 mg/dL; Very High-II (target organ damage [TOD], or cardiovascular risk factors [CVRFs]) <70 mg/dL; high (others) <100 mg/dL. ESC/EAS (2019): Very High-I (ASCVD): <55 mg/dL; Very High-II (TOD or ≥3-CVRF) <55 mg/dL; high (diabetes ≥10 years without TOD plus any CVRF) <70 mg/dL; moderate (diabetes <10 years without CVRF) <100 mg/dL. ADA (2019): Very High-I (ASCVD); Very High-II (age ≥40+ TOD, or any CVRF), for high intensity statin or statin combined with ezetimibe.
Results
Among 2,000 T2DM patients (mean age 62.6 years; male 55.9%; mean glycosylated hemoglobin 7.2%) ASCVD prevalence was 24.7%. Of 1,455 (72.8%) patients treated with statins, 73.9% received monotherapy. According to KDA guidelines, LDL-C target achievement rates were 55.2% in Very High-I and 34.9% in Very High-II patients. With ESC/EAS guidelines, target attainment rates were 26.6% in Very High-I, 15.7% in Very High-II, and 25.9% in high risk patients. Based on ADA guidelines, most patients (78.9%) were very-high risk; however, only 15.5% received high-intensity statin or combination therapy.
Conclusion
According to current dyslipidemia management guidelines, LDL-C goal achievement remains suboptimal in Korean patients with T2DM.

Citations

Citations to this article as recorded by

ROsulord® sAfety for Patients with Dyslipidemia Study: A Non-interventional, Multicenter, Prospective, Observational Study in South Korea
Do Young Kim, Sung Hea Kim, Eung-Ju Kim, Sang-Jin Han, Ji-Yeong Park, Jong-Chan Youn, Hee-Seok Kim, Ji-Eun Jeong, Kyu-Hyung Ryu
Cardiology and Therapy.2025; 14(1): 17. CrossRef
Diabetic Nephropathy: Pathogenesis, Mechanisms, and Therapeutic Strategies
Shivangi Dwivedi, Mukesh Singh Sikarwar
Hormone and Metabolic Research.2025; 57(01): 7. CrossRef
Risk factor control and cardiovascular events in patients with type 2 diabetes mellitus
Do Kyeong Song, Young Sun Hong, Yeon-Ah Sung, Hyejin Lee, Hidetaka Hamasaki
PLOS ONE.2024; 19(2): e0299035. CrossRef
Distinct effects of rosuvastatin and rosuvastatin/ezetimibe on senescence markers of CD8+ T cells in patients with type 2 diabetes mellitus: a randomized controlled trial
Sang-Hyeon Ju, Joung Youl Lim, Minchul Song, Ji Min Kim, Yea Eun Kang, Hyon-Seung Yi, Kyong Hye Joung, Ju Hee Lee, Hyun Jin Kim, Bon Jeong Ku
Frontiers in Endocrinology.2024;[Epub] CrossRef
Monitoring Global Progress in Core Diabetes Control Metrics: Protocol for a Systematic Review of Prevalence (2015–2023)
John McCaffrey, Samira Barbara Jabakhanji, Roopa Mehta, Steven James, Maisoon Mairghani, Dominika Bhatia, Hazel Ní Chonchubhair, Killian Walsh, Barbara Clyne, Edward W. Gregg
HRB Open Research.2024; 7: 27. CrossRef
Real-world evidence evaluation of LDL-C in hospitalized patients: a population-based observational study in the timeframe 2021–2022
Umberto Capece, Chiara Iacomini, Teresa Mezza, Alfredo Cesario, Carlotta Masciocchi, Stefano Patarnello, Andrea Giaccari, Nicoletta Di Giorgi
Lipids in Health and Disease.2024;[Epub] CrossRef
Study Design and Protocol for a Randomized Controlled Trial to Assess Long-Term Efficacy and Safety of a Triple Combination of Ezetimibe, Fenofibrate, and Moderate-Intensity Statin in Patients with Type 2 Diabetes and Modifiable Cardiovascular Risk Factor
Nam Hoon Kim, Juneyoung Lee, Suk Chon, Jae Myung Yu, In-Kyung Jeong, Soo Lim, Won Jun Kim, Keeho Song, Ho Chan Cho, Hea Min Yu, Kyoung-Ah Kim, Sang Soo Kim, Soon Hee Lee, Chong Hwa Kim, Soo Heon Kwak, Yong‐ho Lee, Choon Hee Chung, Sihoon Lee, Heung Yong J
Endocrinology and Metabolism.2024; 39(5): 722. CrossRef
Lipid Management in Korean People With Type 2 Diabetes Mellitus: Korean Diabetes Association and Korean Society of Lipid and Atherosclerosis Consensus Statement
Ye Seul Yang, Hack-Lyoung Kim, Sang-Hyun Kim, Min Kyong Moon
Journal of Lipid and Atherosclerosis.2023; 12(1): 12. CrossRef
Lipid Management in Korean People with Type 2 Diabetes Mellitus: Korean Diabetes Association and Korean Society of Lipid and Atherosclerosis Consensus Statement
Ye Seul Yang, Hack-Lyoung Kim, Sang-Hyun Kim, Min Kyong Moon
Diabetes & Metabolism Journal.2023; 47(1): 1. CrossRef
Management of Dyslipidemia in Patients with Diabetes Mellitus
Kyung Ae Lee
The Journal of Korean Diabetes.2023; 24(3): 111. CrossRef
Association between carotid atherosclerosis and presence of intracranial atherosclerosis using three-dimensional high-resolution vessel wall magnetic resonance imaging in asymptomatic patients with type 2 diabetes
Ji Eun Jun, You-Cheol Hwang, Kyu Jeong Ahn, Ho Yeon Chung, Geon-Ho Jahng, Soonchan Park, In-Kyung Jeong, Chang-Woo Ryu
Diabetes Research and Clinical Practice.2022; 191: 110067. CrossRef

Clinical Diabetes & Therapeutics
Effectiveness and Safety of Adding Basal Insulin Glargine in Patients with Type 2 Diabetes Mellitus Exhibiting Inadequate Response to Metformin and DPP-4 Inhibitors with or without Sulfonylurea: Yu Mi Kang, Chang Hee Jung, Seung-Hwan Lee, Sang-Wook Kim, Kee-Ho Song, Sin Gon Kim, Jae Hyeon Kim, Young Min Cho, Tae Sun Park, Bon Jeong Ku, Gwanpyo Koh, Dol Mi Kim, Byung-Wan Lee, Joong-Yeol Park; Diabetes Metab J. 2019;43(4):432-446. Published online June 19, 2019; DOI: https://doi.org/10.4093/dmj.2018.0092

6,889 View
102 Download
2 Web of Science
3 Crossref

Abstract PDF Supplementary Material PubReader

Background

We aimed to investigate the effectiveness and safety of adding basal insulin to initiating dipeptidyl peptidase-4 (DPP-4) inhibitor and metformin and/or sulfonylurea (SU) in achieving the target glycosylated hemoglobin (HbA1c) in patients with type 2 diabetes mellitus (T2DM).

Methods

This was a single-arm, multicenter, 24-week, open-label, phase 4 study in patients with inadequately controlled (HbA1c ≥7.5%) T2DM despite the use of DPP-4 inhibitor and metformin. A total of 108 patients received insulin glargine while continuing oral antidiabetic drugs (OADs). The primary efficacy endpoint was the percentage of subjects achieving HbA1c ≤7.0%. Other glycemic profiles were also evaluated, and the safety endpoints were adverse events (AEs) and hypoglycemia.

Results

The median HbA1c at baseline (8.9%; range, 7.5% to 11.1%) decreased to 7.6% (5.5% to 11.7%) at 24 weeks. Overall, 31.7% subjects (n=33) achieved the target HbA1c level of ≤7.0%. The mean differences in body weight and fasting plasma glucose were 1.2±3.4 kg and 56.0±49.8 mg/dL, respectively. Hypoglycemia was reported in 36 subjects (33.3%, 112 episodes), all of which were fully recovered. There was no serious AE attributed to insulin glargine. Body weight change was significantly different between SU users and nonusers (1.5±2.5 kg vs. −0.9±6.0 kg, P=0.011).

Conclusion

The combination add-on therapy of insulin glargine, on metformin and DPP-4 inhibitors with or without SU was safe and efficient in reducing HbA1c levels and thus, is a preferable option in managing T2DM patients exhibiting dysglycemia despite the use of OADs.

Citations

Citations to this article as recorded by

The Effect of Insulin Glargine in Control of Diabetes Among Sudanese Patients in 2024: A Cross-Sectional Study
Hiba Abdelgadir, Husam Abdlraheem, Housameldin Ali, Hussam Jadallah, Hind Abdelgadir, Eltoum Elnour, Mosab Ahmed, Ahmed Awad
International Journal of Diabetes and Endocrinology.2025; 10(1): 17. CrossRef
Glycaemic control with add‐on thiazolidinedione or a sodium‐glucose co‐transporter‐2 inhibitor in patients with type 2 diabetes after the failure of an oral triple antidiabetic regimen: A 24‐week, randomized controlled trial
Jaehyun Bae, Ji Hye Huh, Minyoung Lee, Yong‐Ho Lee, Byung‐Wan Lee
Diabetes, Obesity and Metabolism.2021; 23(2): 609. CrossRef
Beneficial effect of anti-diabetic drugs for nonalcoholic fatty liver disease
Kyung-Soo Kim, Byung-Wan Lee
Clinical and Molecular Hepatology.2020; 26(4): 430. CrossRef

Pathophysiology
Factors Related to Blood Intact Incretin Levels in Patients with Type 2 Diabetes Mellitus: Soyeon Yoo, Eun-Jin Yang, Gwanpyo Koh; Diabetes Metab J. 2019;43(4):495-503. Published online February 20, 2019; DOI: https://doi.org/10.4093/dmj.2018.0105

4,693 View
42 Download

Abstract PDF PubReader: Background
We performed this study to identify factors related to intact incretin levels in patients with type 2 diabetes mellitus (T2DM).
Methods
We cross-sectionally analyzed 336 patients with T2DM. Intact glucagon-like peptide 1 (iGLP-1) and intact glucose-dependent insulinotropic polypeptide (iGIP) levels were measured in a fasted state and 30 minutes after ingestion of a standard mixed meal. The differences between 30 and 0 minute iGLP-1 and iGIP levels were indicated as ΔiGLP-1 and ΔiGIP.
Results
In simple correlation analyses, fasting iGLP-1 was positively correlated with glucose, C-peptide, creatinine, and triglyceride levels, and negatively correlated with estimated glomerular filtration rate. ΔiGLP-1 was positively correlated only with ΔC-peptide levels. Fasting iGIP showed positive correlations with glycosylated hemoglobin (HbA1c) and fasting glucose levels, and negative correlations with ΔC-peptide levels. ΔiGIP was negatively correlated with diabetes duration and HbA1c levels, and positively correlated with Δglucose and ΔC-peptide levels. In multivariate analyses adjusting for age, sex, and covariates, fasting iGLP-1 levels were significantly related to fasting glucose levels, ΔiGLP-1 levels were positively related to ΔC-peptide levels, fasting iGIP levels were related to fasting C-peptide levels, and ΔiGIP levels were positively related to ΔC-peptide and Δglucose levels.
Conclusion
Taken together, intact incretin levels are primarily related to C-peptide and glucose levels. This result suggests that glycemia and insulin secretion are the main factors associated with intact incretin levels in T2DM patients.

Changes in Adenosine Deaminase Activity in Patients with Type 2 Diabetes Mellitus and Effect of DPP-4 Inhibitor Treatment on ADA Activity: Jae-Geun Lee, Dong Gu Kang, Jung Re Yu, Youngree Kim, Jinsoek Kim, Gwanpyo Koh, Daeho Lee; Diabetes Metab J. 2011;35(2):149-158. Published online April 30, 2011; DOI: https://doi.org/10.4093/dmj.2011.35.2.149

5,642 View
44 Download
29 Crossref

Abstract PDF PubReader

Background

Dipeptidyl peptidase 4 (DPP-4, also known as CD26) binds with adenosine deaminase (ADA) to activate T lymphocytes. Here, we investigated whether ADA activity is specifically affected by treatment with DPP-4 inhibitor (DPP4I) compared with other anti-diabetic agents.

Methods

Fasting ADA activity, in addition to various metabolic and biochemical parameters, were measured in 262 type 2 diabetes mellitus (T2DM) patients taking various anti-diabetic agents and in 46 non-diabetic control subjects.

Results

ADA activity was increased in T2DM patients compared with that in non-diabetic control subjects (mean±standard error, 23.1±0.6 U/L vs. 18.6±0.8 U/L; P<0.05). ADA activity was correlated with fasting plasma glucose (r=0.258, P<0.05), HbA1c (r=0.208, P<0.05), aspartate aminotransferase (r=0.325, P<0.05), and alanine aminotransferase (r=0.248, P<0.05). Compared with the well-controlled T2DM patients (HbA1c<7%), the poorly controlled group (HbA1c>9%) showed significantly increased ADA activity (21.1±0.8 U/L vs. 25.4±1.6 U/L; P<0.05). The effect of DPP4I on ADA activity in T2DM patients did not differ from those of other oral anti-diabetic agents or insulin. T2DM patients on metformin monotherapy showed a lower ADA activity (20.9±1.0 U/L vs. 28.1±2.8 U/L; P<0.05) compared with that of those on sulfonylurea monotherapy.

Conclusion

Our results show that ADA activity is increased in T2DM patients compared to that in non-diabetic patients, is positively correlated with blood glucose level, and that DPP4I has no additional specific effect on ADA activity, except for a glycemic control- or HbA1c-dependent effect.

Citations

Citations to this article as recorded by

Pharmacokinetics of islatravir in participants with moderate hepatic impairment
Randolph P. Matthews, Munjal Patel, Wen Liu, Yang Liu, Juan C. Rondón, Ryan C. Vargo, S. Aubrey Stoch, Marian Iwamoto, Miguel Angel Martinez
Antimicrobial Agents and Chemotherapy.2025;[Epub] CrossRef
Influence of BMI on adenosine deaminase and stroke outcomes in mechanical thrombectomy subjects
Benton Maglinger, Christopher J. McLouth, Jacqueline A. Frank, Chintan Rupareliya, Madison Sands, Lila Sheikhi, Shivani Pahwa, David Dornbos, Jordan P. Harp, Amanda L. Trout, Jadwiga Turchan-Cholewo, Ann M. Stowe, Justin F. Fraser, Keith R. Pennypacker
Brain, Behavior, & Immunity - Health.2022; 20: 100422. CrossRef
Glutamine restores testicular glutathione-dependent antioxidant defense and upregulates NO/cGMP signaling in sleep deprivation-induced reproductive dysfunction in rats
M.A. Hamed, T.M. Akhigbe, R.E. Akhigbe, A.O. Aremu, P.A. Oyedokun, J.A. Gbadamosi, P.E. Anifowose, M.A. Adewole, O.O. Aboyeji, H.O. Yisau, G.O. Tajudeen, M.M. Titiloye, N.F. Ayinla, A.F. Ajayi
Biomedicine & Pharmacotherapy.2022; 148: 112765. CrossRef
Effects of quercetin and metabolites on uric acid biosynthesis and consequences for gene expression in the endothelium
Sarka Tumova, Yuanlu Shi, Ian M. Carr, Gary Williamson
Free Radical Biology and Medicine.2021; 162: 191. CrossRef
The value of adenosine deaminase activity in latent autoimmune diabetes in adults and type 2 diabetes patients
Yu Zhou, Wei-Dong Jin, Zhen-Zhen Pang, Jun Xia, Su-Feng Chen
International Journal of Diabetes in Developing Countries.2021; 41(1): 48. CrossRef
Purinergic signaling in diabetes and metabolism
Shanu Jain, Kenneth A. Jacobson
Biochemical Pharmacology.2021; 187: 114393. CrossRef
Berberine modulates crucial erectogenic biomolecules and alters histological architecture in penile tissues of diabetic rats
Stephen Adeniyi Adefegha, Ganiyu Oboh, Felix Abayomi Dada, Sunday Idowu Oyeleye, Bathlomew Maduka Okeke
Andrologia.2021;[Epub] CrossRef
Suppression of uric acid and lactate production by sodium acetate ameliorates hepatic triglyceride accumulation in fructose-insulin resistant pregnant rats
Adewumi O. Oyabambi, Kehinde S. Olaniyi, Ayodele O. Soladoye, Lawrence A. Olatunji
Environmental Toxicology and Pharmacology.2020; 80: 103452. CrossRef
Therapeutic Perspectives of Adenosine Deaminase Inhibition in Cardiovascular Diseases
Barbara Kutryb-Zajac, Paulina Mierzejewska, Ewa M. Slominska, Ryszard T. Smolenski
Molecules.2020; 25(20): 4652. CrossRef
Adenosine as a Marker and Mediator of Cardiovascular Homeostasis: A Translational Perspective
Trevor Simard, Richard Jung, Alisha Labinaz, Mohammad Ali Faraz, F. Daniel Ramirez, Pietro Di Santo, Ian Pitcher, Pouya Motazedian, Chantal Gaudet, Rebecca Rochman, Jeffrey Marbach, Paul Boland, Kiran Sarathy, Saleh Alghofaili, Juan J. Russo, Etienne Cout
Cardiovascular & Hematological Disorders-Drug Targets.2019; 19(2): 109. CrossRef
Mineralocorticoid receptor blockade attenuates disrupted glutathione-dependent antioxidant defense and elevated endoglin in the hearts of pregnant rats exposed to testosterone
Taofeek O. Usman, Olufunto O. Badmus, InKyeom Kim, Lawrence A. Olatunji
Naunyn-Schmiedeberg's Archives of Pharmacology.2019; 392(7): 773. CrossRef
Serum activities of dipeptidyl peptidase-4 and adenosine deaminase in polycystic ovary syndrome: association with obesity
Seda Kahraman, Alev Eroglu Altinova, Serenay Elgun, Mehmet Muhittin Yalcin, Banu Aktas Yilmaz, Cigdem Ozkan, Mujde Akturk, Fusun Balos Toruner
Gynecological Endocrinology.2019; 35(8): 714. CrossRef
Serum adenosine deaminase activity and coronary artery disease: a retrospective case-control study based on 9929 participants
Chao Xuan, Qing-Wu Tian, Shao-Yan Zhang, Hui Li, Ting-Ting Tian, Peng Zhao, Kang Yue, Yan-Yan Ling, Guo-Wei He, Li-Min Lun
Therapeutic Advances in Chronic Disease.2019;[Epub] CrossRef
Metabolites related to purine catabolism and risk of type 2 diabetes incidence; modifying effects of the TCF7L2-rs7903146 polymorphism
Christopher Papandreou, Jun Li, Liming Liang, Mònica Bulló, Yan Zheng, Miguel Ruiz-Canela, Edward Yu, Marta Guasch-Ferré, Cristina Razquin, Clary Clish, Dolores Corella, Ramon Estruch, Emilio Ros, Montserrat Fitó, Fernando Arós, Lluís Serra-Majem, Nuria R
Scientific Reports.2019;[Epub] CrossRef
Current status of G-protein coupled receptors as potential targets against type 2 diabetes mellitus
Mehboob Hoque, Safdar Ali, Muddasarul Hoda
International Journal of Biological Macromolecules.2018; 118: 2237. CrossRef
Endoglin inhibition by sodium acetate and flutamide ameliorates cardiac defective G6PD-dependent antioxidant defense in gestational testosterone-exposed rats
Lawrence A. Olatunji, Emmanuel D. Areola, Olufunto O. Badmus
Biomedicine & Pharmacotherapy.2018; 107: 1641. CrossRef
Sodium acetate and androgen receptor blockade improve gestational androgen excess-induced deteriorated glucose homeostasis and antioxidant defenses in rats: roles of adenosine deaminase and xanthine oxidase activities
Taofeek O. Usman, Emmanuel D. Areola, Olufunto O. Badmus, InKyeom Kim, Lawrence A. Olatunji
The Journal of Nutritional Biochemistry.2018; 62: 65. CrossRef
ADENOSINE DEAMINASE ACTIVITY IN TYPE 2 DIABETES MELLITUS
Farija Peruvankuzhiyil, Lavanya Madhavan, Manaloor George Joseraj
Journal of Evidence Based Medicine and Healthcare.2017; 4(5): 238. CrossRef
Adenosine signaling in diabetes mellitus and associated cardiovascular and renal complications
Maria Peleli, Mattias Carlstrom
Molecular Aspects of Medicine.2017; 55: 62. CrossRef
The Adenosinergic System in Diabetic Retinopathy
J. Vindeirinho, A. R. Santiago, C. Cavadas, A. F. Ambrósio, P. F. Santos
Journal of Diabetes Research.2016; 2016: 1. CrossRef
Upregulation of inducible NO synthase by exogenous adenosine in vascular smooth muscle cells activated by inflammatory stimuli in experimental diabetes
Alberto Nassi, Francesca Malorgio, Serena Tedesco, Andrea Cignarella, Rosa Maria Gaion
Cardiovascular Diabetology.2016;[Epub] CrossRef
Reduced adenosine A2a receptor–mediated efferent arteriolar vasodilation contributes to diabetes-induced glomerular hyperfiltration
Patrik Persson, Peter Hansell, Fredrik Palm
Kidney International.2015; 87(1): 109. CrossRef
CD26/DPP4 Levels in Peripheral Blood and T Cells in Patients With Type 2 Diabetes Mellitus
Sang Ah Lee, Young Ree Kim, Eun Jin Yang, Eun-Jeong Kwon, Sun Hyung Kim, Sung Ha Kang, Doek Bae Park, Byung-Chul Oh, Jinseok Kim, Sang Taek Heo, Gwanpyo Koh, Dae Ho Lee
The Journal of Clinical Endocrinology & Metabolism.2013; 98(6): 2553. CrossRef
Raised Serum Adenosine Deaminase Level in Nonobese Type 2 Diabetes Mellitus
Vineet Kumar Khemka, Debajit Bagchi, Arindam Ghosh, Oishimaya Sen, Aritri Bir, Sasanka Chakrabarti, Anindita Banerjee, R. E. Felberbaum, V. Sánchez-Margalet, S. Ulisse
The Scientific World Journal.2013;[Epub] CrossRef
Phosphodiesterase III Inhibition Increases cAMP Levels and Augments the Infarct Size Limiting Effect of a DPP-4 Inhibitor in Mice with Type-2 Diabetes Mellitus
Yochai Birnbaum, Alexander C. Castillo, Jinqiao Qian, Shukuan Ling, Hongmei Ye, Jose R. Perez-Polo, Mandeep Bajaj, Yumei Ye
Cardiovascular Drugs and Therapy.2012; 26(6): 445. CrossRef
Serum Adenosine deaminase activity in type 2 Diabetes Mellitus patients
M. N. Vanitha Gowda, K. C. Vasudha, S. Reshma, K. J. Sujatha
International Journal of Diabetes in Developing Countries.2012; 32(3): 176. CrossRef
Cyclic AMP and PKA: How can a Lot of Good Come from the Potentially Bad?
Barbara Huisamen
Cardiovascular Drugs and Therapy.2012; 26(6): 435. CrossRef
Gadd45α: A Novel Diabetes-Associated Gene Potentially Linking Diabetic Cardiomyopathy and Baroreflex Dysfunction
Ning Wang, Chao Yang, Fang Xie, Lihua Sun, Xiaolin Su, Ying Wang, Ran Wei, Rong Zhang, Xia Li, Baofeng Yang, Jing Ai, Rajesh Gopalrao Katare
PLoS ONE.2012; 7(12): e49077. CrossRef
The CD39-Adenosinergic Axis in the Pathogenesis of Immune and Nonimmune Diabetes
Joanne S. J. Chia, Jennifer L. McRae, Peter J. Cowan, Karen M. Dwyer
Journal of Biomedicine and Biotechnology.2012; 2012: 1. CrossRef

Clinical Characteristics of Type 2 Diabetes Patients according to Family History of Diabetes: Seung Uk Jeong, Dong Gu Kang, Dae Ho Lee, Kang Woo Lee, Dong-Mee Lim, Byung Joon Kim, Keun-Yong Park, Hyoun-Jung Chin, Gwanpyo Koh; Korean Diabetes J. 2010;34(4):222-228. Published online August 31, 2010; DOI: https://doi.org/10.4093/kdj.2010.34.4.222

4,709 View
30 Download
18 Crossref

Abstract PDF PubReader

Background

Type 2 diabetes mellitus (T2DM) has a strong genetic component, and its prevalence is notably increased in the family members of T2DM patients. However, there are few studies about the family history of T2DM. We carried out this study to assess the influences of family history on clinical characteristics in T2DM patients.

Methods

This is a cross-sectional study involving 651 T2DM patients. Patient history and physical examination were performed and fasting blood was taken. If any first degree relative was diabetic, a family history of diabetes was considered to exist.

Results

Among the total 621 patients, 38.4% had a family history of diabetes. Patients with a family history had a younger age, higher weight, younger age at diagnosis and higher triglyceride level than did those without a family history. Dyslipidemia medication and metabolic syndrome were more prevalent in familial diabetes. Sex, blood pressure, previous treatment for diabetes, HbA1c, C-peptide, total cholesterol, high density lipoprotein cholesterol, and low density lipoprotein cholesterol were not different between familial and non-familial diabetes. Upon multiple linear regression analysis, the family history of diabetes remained significantly associated with serum triglyceride level.

Conclusion

In T2DM patients with a family history of diabetes, the disease tended to develop earlier. Metabolic syndrome and cardiovascular risk factors are more prevalent in familial T2DM than they were in non-familial T2DM. These results support the necessity of earlier screening for diabetes in family members of T2DM patients and more active prevention against cardiovascular disease in T2DM patients with a family history.

Citations

Citations to this article as recorded by

Emerging role of hsa_circ_0000652, hsa-miR-21, SMAD2, and Foxo1 in type 2 diabetes mellitus pathogenesis
Abeer Mostafa, Azza Abusree, Radwa T.M. Hassanien, Hala Mahfouz, Marwa Salah, Heba M. Amr, Sally A. Fahim
Human Gene.2025; : 201386. CrossRef
COVID-19-Induced Diabetes Mellitus: Comprehensive Cellular and Molecular Mechanistic Insights
Praise Tatenda Nhau, Mlindeli Gamede, Ntethelelo Sibiya
Pathophysiology.2024; 31(2): 197. CrossRef
Positive parental history of diabetes is associated with early diagnosis, better dietary compliance, and glycemic control among type 2 diabetes patients in southern Sri Lanka
Warsha De Zoysa, Thilak Priyantha Weerarathna, Keddagoda Gamage Piyumi Wasana, Miyuru Kavinda Weerarathna, Vidarsha Senadeera
Diabetology & Metabolic Syndrome.2024;[Epub] CrossRef
Effects of Propolis Consumption on Glycemic Indices and Liver Enzymes in Adults: A Grading of Recommendations Assessment, Development, and Valuation-assessed Systematic Review and Dose-Response Meta-analysis
Shaghayegh Adeli, Mahsa Maroofi, Fatemeh Pourteymour Fard Tabrizi, Beitullah Alipour, Marzieh Heidari, Mahdi Vajdi, Mahdieh Abbasalizad-Farhangi
Clinical Therapeutics.2024; 46(9): e6. CrossRef
Evolutionary algorithm for the optimization of meal intake and insulin administration in patients with type 2 diabetes
Eva Gonzalez-Flo, Elaheh Kheirabadi, Carlos Rodriguez-Caso, Javier Macía
Frontiers in Physiology.2023;[Epub] CrossRef
Role of Cytokines (IL-17 and IL-33), FGF-18, and WNT-5 in the Pathogenesis of Patients with Established Type II Diabetes
Przha Mohammed, Kawa Amin
Journal of Zankoy Sulaimani - Part A.2023; 25(2): 11. CrossRef
Cellular Chitchatting: Exploring the Role of Exosomes as Cardiovascular Risk Factors
Giulia Germena, Laura Cecilia Zelarayán, Rabea Hinkel
Frontiers in Cell and Developmental Biology.2022;[Epub] CrossRef
Combined associations of family history and self-management with age at diagnosis and cardiometabolic risk in 86,931 patients with type 2 diabetes: Joint Asia Diabetes Evaluation (JADE) Register from 11 countries
Johnny T. K. Cheung, Eric Lau, Cyrus C. T. Tsui, Edmond L. N. Siu, Naomi K. W. Tse, Nicole Y. L. Hui, Ronald C. W. Ma, Alice P. S. Kong, Amy Fu, Vanessa Lau, Weiping Jia, Wayne H. H. Sheu, Leorino Sobrepena, K. H. Yoon, Alexander T. B. Tan, Yook-Chin Chia
BMC Medicine.2022;[Epub] CrossRef
Capsaicin, its clinical significance in patients with painful diabetic neuropathy
Phiwayinkosi V. Dludla, Bongani B. Nkambule, Ilenia Cirilli, Fabio Marcheggiani, Sihle E. Mabhida, Khanyisani Ziqubu, Yonela Ntamo, Babalwa Jack, Tawanda M. Nyambuya, Sidney Hanser, Sithandiwe E. Mazibuko-Mbeje
Biomedicine & Pharmacotherapy.2022; 153: 113439. CrossRef
Safety profile of sodium glucose co-transporter 2 (SGLT2) inhibitors: A brief summary
Annamaria Mascolo, Raffaella Di Napoli, Nunzia Balzano, Donato Cappetta, Konrad Urbanek, Antonella De Angelis, Lucia Scisciola, Irene Di Meo, Maria Giuseppa Sullo, Concetta Rafaniello, Liberata Sportiello
Frontiers in Cardiovascular Medicine.2022;[Epub] CrossRef
Impact of triglycerides and waist circumference on insulin resistance and β-cell function in non-diabetic first-degree relatives of type 2 diabetes
Fahd Ahmed, Molham AL-Habori, Ebtesam Al-Zabedi, Riyadh Saif-Ali
BMC Endocrine Disorders.2021;[Epub] CrossRef
Orientin Improves Substrate Utilization and the Expression of Major Genes Involved in Insulin Signaling and Energy Regulation in Cultured Insulin-Resistant Liver Cells
Sithandiwe E. Mazibuko-Mbeje, Sinenhlanhla X. H. Mthembu, Andani Tshiitamune, Ndivhuwo Muvhulawa, Fikile T. Mthiyane, Khanyisani Ziqubu, Christo J. F. Muller, Phiwayinkosi V. Dludla
Molecules.2021; 26(20): 6154. CrossRef
Identification of Pre-Diabetic Biomarkers in the Progression of Diabetes Mellitus
Jae-Ho Lee, Do-Young Kim, Rubee Pantha, Eun-Ho Lee, Jae-Hoon Bae, Eugene Han, Dae-Kyu Song, Taeg Kyu Kwon, Seung-Soon Im
Biomedicines.2021; 10(1): 72. CrossRef
Shared (epi)genomic background connecting neurodegenerative diseases and type 2 diabetes
Valerio Caputo, Andrea Termine, Claudia Strafella, Emiliano Giardina, Raffaella Cascella
World Journal of Diabetes.2020; 11(5): 155. CrossRef
Family history of diabetes in both parents is strongly associated with impaired residual β‐cell function in Japanese type 2 diabetes patients
Minoru Iwata, Yutaka Kamura, Hisae Honoki, Kaori Kobayashi, Manabu Ishiki, Kunimasa Yagi, Yasuo Fukushima, Atsuko Takano, Hiromi Kato, Shihou Murakami, Kiyohiro Higuchi, Chikaaki Kobashi, Kazuhito Fukuda, Yukiko Koshimizu, Kazuyuki Tobe
Journal of Diabetes Investigation.2020; 11(3): 564. CrossRef
The relationship between age of onset and risk factors including family history and life style in Korean population with type 2 diabetes mellitus
Jin-Won Noh, Jin Hee Jung, Jeong Eun Park, Jung Hwa Lee, Kang Hee Sim, Jumin Park, Min Hee Kim, Ki-Bong Yoo
Journal of Physical Therapy Science.2018; 30(2): 201. CrossRef
Clinical Characteristics of Subjects with Sulfonylurea-Dependent Type 2 Diabetes
Se Hee Min, Soo Heon Kwak, Young Min Cho, Kyong Soo Park, Hye Seung Jung
Endocrinology and Metabolism.2015; 30(4): 509. CrossRef
Nutritional Assessment of Type II Diabetic Patients
El-Sayed H. Bakr
Pakistan Journal of Nutrition.2015; 14(6): 308. CrossRef

Author index